Retatrutide injection sites follow the same subcutaneous principles as other licensed GLP-1 class therapies, making correct technique essential for safety and efficacy. Retatrutide is an investigational triple agonist (GIP, GLP-1, and glucagon receptor) not yet approved by the MHRA or EMA, and should only be used within regulated clinical trials or authorised supply channels. Understanding where to inject retatrutide, how to rotate sites, and how to avoid common errors can help ensure the medication is delivered correctly, minimise discomfort, and reduce the risk of complications such as lipohypertrophy or infection.

Recommended Injection Sites for Retatrutide

Retatrutide is injected subcutaneously into the abdomen, front thigh, or outer upper arm, with the abdomen being the most accessible and commonly used site for self-administration.

Retatrutide is an investigational triple agonist peptide (GIP, GLP-1, and glucagon receptor) currently under clinical development for the management of obesity and type 2 diabetes.^[1][2] It has not yet received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) at the time of writing. Retatrutide should only be used within the context of a regulated clinical trial or, once licensed, through authorised supply channels. Do not attempt to obtain or use retatrutide from unregulated online sources, as product quality, safety, and dosing cannot be assured outside regulated supply.

Like other injectable peptide therapies in its class, retatrutide is administered subcutaneously — meaning it is injected into the fatty tissue just beneath the skin, rather than into muscle or a vein.^[4][5]

The three primary subcutaneous injection sites used for comparable licensed therapies (such as semaglutide and tirzepatide, as described in their UK Summary of Product Characteristics) are:

• Abdomen – the area around the stomach, avoiding the area immediately around the navel

• Front (anterolateral) thigh – the outer-front portion of the upper thigh

• Upper arms – the outer area of the upper arm, typically requiring assistance from another person for self-administration

The abdomen is generally considered the most accessible and commonly used site, as it offers a relatively large surface area of subcutaneous fat and is straightforward to self-administer. The front thigh is a practical alternative, particularly for individuals who find abdominal injections uncomfortable. The upper arm is less commonly used for self-injection due to the difficulty of accessing the correct area unassisted.

Guidance on injection technique for retatrutide is extrapolated from established subcutaneous injectable therapies such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro), which share a similar administration route.^[4][5] Always follow the specific instructions provided by your prescribing clinician or the product's patient information leaflet (PIL) once available.

How to Choose the Right Injection Site

The best injection site has adequate subcutaneous fat, intact skin, and is easily accessible; avoid areas with bruising, scarring, or lipohypertrophy, as these impair drug absorption.

Choosing the most appropriate injection site is an important aspect of safe and effective subcutaneous administration. The right site will depend on several individual factors, including body composition, personal comfort, ease of access, and any pre-existing skin conditions at potential injection areas.

When selecting a site, consider the following:

• Adequate subcutaneous fat – The site should have sufficient fatty tissue to allow the needle to reach the subcutaneous layer without penetrating muscle. Individuals with lower body fat may find the abdomen or thigh more suitable than the upper arm.

• Skin integrity – Avoid areas with bruising, scarring, stretch marks, lipohypertrophy (thickened or lumpy skin from repeated injections), active skin infections, or broken skin. Injecting into compromised tissue can impair drug absorption and increase the risk of local reactions.

• Comfort and accessibility – The site should be one you can reach comfortably and consistently. For most people, the abdomen offers the greatest ease of self-administration.

• Consistency with rotation – Whichever site you choose, it should be part of a structured rotation plan (discussed further below) to prevent tissue damage over time.

If you take anticoagulant or antiplatelet medicines, or have a bleeding disorder, apply gentle pressure to the injection site after withdrawing the needle. Seek advice from your prescribing clinician if you experience significant or persistent bruising.

If you are unsure which site is most appropriate for your individual circumstances, speak with your prescribing clinician, diabetes specialist nurse, or pharmacist. They can assess your body composition and injection technique to provide personalised guidance, in line with evidence-based UK injection technique recommendations (such as those published by the Forum for Injection Technique UK).^[6] People with certain conditions — such as significant lipodystrophy or a history of skin reactions to injectable medications — may require additional clinical input before beginning treatment.

Step-by-Step Guide to Injecting Retatrutide Safely

Safe subcutaneous injection requires clean hands, inspection of the device, correct needle angle (typically 90°), slow plunger depression, and immediate sharps disposal without recapping.

Safe injection technique is essential to ensure the medication is delivered correctly, minimise discomfort, and reduce the risk of complications such as infection or poor drug absorption. The following guidance is based on best practice for subcutaneous injectable therapies and should be adapted in line with any specific instructions provided in the retatrutide product PIL once licensed.

Before injecting:

• Wash your hands thoroughly with soap and water for at least 20 seconds.

• Gather all necessary equipment: the pre-filled pen or syringe, a new needle (if applicable), and a sharps disposal container.

• Check the expiry date on the device or packaging. Do not use if the product has expired.

• Inspect the medication: check for discolouration, visible particles, or damage to the device. Do not use if the solution appears abnormal.

• Allow the medication to reach room temperature if it has been refrigerated (typically 15–30 minutes), as cold injections can be more uncomfortable.

• If the device requires priming before first use, follow the instructions in the PIL.

During the injection:

• Clean the chosen skin area by washing with soap and water; if you use an alcohol swab, allow the skin to dry fully before injecting.

• Gently pinch the skin to lift the subcutaneous tissue, particularly if you have a lower body fat percentage.

• Insert the needle at the angle specified in the device PIL (commonly 90 degrees; 45 degrees may be advised for thinner individuals or shorter needles).

• Depress the plunger or activation button slowly and steadily.

• Hold the device in place for the duration specified in the PIL (often around 5–10 seconds) after injection to ensure full dose delivery before withdrawing.

After injecting:

• Do not rub the injection site, as this can cause irritation or affect absorption.

• Do not recap the needle, as this significantly increases the risk of needlestick injury.

• Dispose of the used needle or device immediately in an approved sharps bin (see the section on common mistakes below for UK disposal guidance).

• Record the site used to support your rotation schedule.

Rotating Injection Sites to Reduce Skin Reactions

Rotating injection sites — moving at least 1–2 cm from the previous spot and alternating between body regions — prevents lipohypertrophy and ensures consistent drug absorption.

Site rotation is a fundamental principle of subcutaneous injection therapy. Repeatedly injecting into the same spot can lead to lipohypertrophy — a condition where fatty lumps develop under the skin due to localised tissue trauma. Lipohypertrophy not only causes cosmetic changes but can impair drug absorption, leading to unpredictable medication levels and reduced therapeutic effect. This has been well documented with insulin therapy and can also occur with GLP-1 receptor agonist injectables.

A structured rotation plan helps distribute tissue stress evenly across multiple sites. In line with UK injection technique guidance (Forum for Injection Technique UK), a practical approach includes:

• Rotating within each injection zone – For example, move systematically around the abdomen, ensuring each new injection is at least 1–2 cm away from the previous one within the same region, and avoid reusing the exact same spot.^[6]

• Alternating between body regions – Rotate not just within one area (e.g., the abdomen) but also between the abdomen, front thighs, and upper arms over time, allowing each area adequate recovery between uses.

• Keeping a simple injection diary – Note the date, site, and any local reactions after each injection. This helps identify patterns and ensures no single area is overused.

• Avoiding damaged or abnormal skin – Do not inject into areas of lipohypertrophy, scarring, or active skin changes.

If you notice persistent lumps, hardened areas, or changes in skin texture at injection sites, inform your healthcare provider promptly. These changes may indicate lipohypertrophy and could warrant a temporary or permanent change in injection location. Regular review of injection sites by a clinician or diabetes specialist nurse is recommended for anyone on long-term injectable therapy.

Common Mistakes to Avoid When Injecting Retatrutide

The most common injection errors include injecting into muscle, reusing needles, skipping site rotation, injecting cold medication, and unsafe sharps disposal, all of which compromise safety or treatment effectiveness.

Even with the best intentions, certain errors in injection technique are common and can compromise both safety and treatment effectiveness. Being aware of these pitfalls can help you administer retatrutide — or any subcutaneous injectable — more confidently and correctly.

Injecting into muscle rather than subcutaneous fat is one of the most frequent mistakes, particularly in individuals with low body fat. Intramuscular injection can cause increased pain, faster drug absorption than intended, and a higher risk of bruising.^[8] Using the correct needle length and pinching the skin can help avoid this.

Reusing needles is another common error. Needles become blunt after a single use, making subsequent injections more painful and increasing the risk of skin trauma and infection.^[9][10] Always use a fresh, sterile needle for each injection.

Recapping needles significantly increases the risk of accidental needlestick injury. Place used needles directly into the sharps bin without recapping.

Skipping site rotation — as discussed above — can lead to lipohypertrophy and inconsistent drug absorption. Even if one site feels more comfortable, it is important to rotate systematically.

Injecting cold medication directly from the refrigerator can cause stinging and discomfort. Allow the pen or syringe to sit at room temperature for 15–30 minutes before use.

Unsafe sharps disposal poses a risk to others, including household members and waste collection staff. To dispose of sharps safely in the UK: request a sharps bin from your GP surgery or community pharmacy; follow your local council or Integrated Care Board (ICB) arrangements for collection or return — some pharmacies accept returns, but provision varies by area.^[11] Never place sharps in household waste or recycling. Check NHS guidance or contact your GP surgery for local arrangements.

Never share injection devices or needles with another person, even if the needle is changed. This carries a serious risk of bloodborne infection transmission.

Seek urgent help if you experience warning signs. If you develop signs of a severe allergic reaction — such as swelling of the face, lips, or throat, difficulty breathing, or a widespread rash — call 999 immediately. For rapidly spreading redness, significant swelling, severe pain, or fever at an injection site, seek same-day assessment by contacting NHS 111 or your GP.

If you experience any suspected side effects from retatrutide or any injectable medicine, you can report these via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps the MHRA monitor the safety of medicines and medical devices in the UK.

Frequently Asked Questions